- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Orciprenaline, also known as metaproterenol, is a bronchodilator used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is a beta-2 agonist, meaning it works by stimulating beta-2 receptors in the lungs, which relaxes the muscles in the airways and increases airflow. Orciprenaline is available in both oral and inhaled forms, and is often used in combination with other medications to treat more severe cases of respiratory diseases.
Orciprenaline is a widely used drug in the respiratory market, and is often prescribed as a first-line treatment for asthma and COPD. It is also used to treat other respiratory conditions such as bronchitis and emphysema. The drug is available in many countries around the world, and is often prescribed in combination with other medications to treat more severe cases of respiratory diseases.
Companies in the Orciprenaline market include GlaxoSmithKline, Merck, Pfizer, and AstraZeneca. Show Less Read more